Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 1/20 | 0.46 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | DUT | P33316 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4094755 | 0.82 | TK1 (0.63) | TK1UPP1SMN1; SMN2LMNACYP2C9 | |
| SCHEMBL1829505 | 0.82 | TK1 (0.47) | TK1UPP1TDP1ALDH1A1MAPK1 | |
| SCHEMBL10457105 | 0.82 | KMT2A (0.43) | UPP1CYP2C9ALDH1A1 | |
| SCHEMBL1830845 | 0.78 | TK1 (0.47) | TK1TDP1SMN1; SMN2ALDH1A1DAO | |
| SCHEMBL1838508 | 0.78 | UPP1 (0.53) | UPP1 | |
| SCHEMBL8707821 | 0.71 | TK1 (0.64) | TK1MAPK1 | |
| SCHEMBL11396309 | 0.70 | TK1 (0.50) | TK1UPP1TDP1LMNAMAPK1 | |
| Propene SCHEMBL16044977 | 0.70 | LMNA (0.61) | TDP1SMN1; SMN2LMNAALDH1A1MAPK1 | |
| Ethylene SCHEMBL8002940 | 0.69 | TDP1 (0.68) | TDP1SMN1; SMN2LMNAALDH1A1MAPK1 | |
| SCHEMBL3870579 | 0.69 | TDP1 (0.73) | TDP1SMN1; SMN2LMNAALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227594-B2 | Antiviral nucleosides | Kumar, Rakesh (CA) | 2012-07-24 | — | — | US | disclosed |
| US-8227594-B2 | Antiviral nucleosides | Kumar, Rakesh (CA) | 2012-07-24 | — | — | US | disclosed |
| EP-2322534-A1 | Antiviral nucleosides | Kumar, Rakesh (CA) | 2011-05-18 | — | — | EP | disclosed |
| US-20100130440-A1 | ANTIVIRAL NUCLEOSIDES | KUMAR, RAKESH (CA) | 2010-05-27 | — | — | US | disclosed |
| US-20100130440-A1 | ANTIVIRAL NUCLEOSIDES | KUMAR, RAKESH (CA) | 2010-05-27 | — | — | US | disclosed |
| US-7589077-B2 | such as 5-iodo-O6-5'-cyclo-5,6-dihydro-3'-azido-3'-deoxythymidine for prophylaxis or diagnosis of viral diseases caused by hepatitis virus, herpes viruses such as Epstein-Barr virus | Kumar, Rakesh (CA) | 2009-09-15 | — | — | US | disclosed |
| US-7589077-B2 | such as 5-iodo-O6-5'-cyclo-5,6-dihydro-3'-azido-3'-deoxythymidine for prophylaxis or diagnosis of viral diseases caused by hepatitis virus, herpes viruses such as Epstein-Barr virus | Kumar, Rakesh (CA) | 2009-09-15 | — | — | US | disclosed |
| US-20040242533-A1 | Antiviral nucleosides | KUMAR, RAKESH (CA) | 2004-12-02 | — | — | US | disclosed |
| EP-1387850-A2 | ANTIVIRAL NUCLEOSIDES | Kumar, Rakesh (CA) | 2004-02-11 | — | — | EP | disclosed |
| WO-2002094844-A2 | ANTIVIRAL NUCLEOSIDES | KUMAR RAKESH (CA) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242533-A1 | Antiviral nucleosides | ENTPD5, DUT, ADA | TK1 49/4885UPP1 92/4885TDP1 769/4885 |
| US-20100130440-A1 | ANTIVIRAL NUCLEOSIDES | PNP, ENTPD5, ADA | TK1 59/4885UPP1 64/4885TDP1 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.